Article

NDA accepted for kidney cancer agent

AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.

Related Videos
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Related Content
© 2025 MJH Life Sciences

All rights reserved.